Status:
UNKNOWN
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Lead Sponsor:
New York Medical College
Conditions:
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of ...
Detailed Description
Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Relapsed or refractory acute lymphoblastic leukemia,
- Burkitts leukemia/lymphoma,
- Lymphoid blastic CML,
- Lymphoblastic lymphoma.
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01513603
Start Date
January 1 2012
End Date
January 1 2014
Last Update
January 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Westchester Medical Center/New York Medical College
Valhalla, New York, United States, 10595